摘要:
The invention comprises use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium and a mixture of any thereof in the manufacture of a food product, dietary supplement or medicament for lowering tissue inflammation (in particular, adipose, liver or muscle tissue inflammation) and treating cardiovascular disease in a mammal. The lactic acid bacteria and/or Bifidobacteria can also be used to treat diabetes and insulin resistance and induce enhanced secretion of insulin upon a glucose challenge and lower blood glucose levels without a concomitant decrease in weight gain.
摘要:
The invention relates to use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.
摘要:
The invention relates to use of a bacterium selected from a lactic acid bacterium, a Bifidobacterium or a mixture of any thereof for treating metabolic endotoxemia, inhibiting bacterial translocation and regulating lipid absorption in a mammal.
摘要:
This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.
摘要:
The present invention relates to a method of treating or prophlaxis of a respiratory tract illness in a subject comprising administering to said subject a composition comprising Bifidobacterium lactis BL04 and/or fermentation product of Bifidobacterium lactis BL04 and/or a cell lysate of Bifidobacterium lactis BL04.